E2082 Discontinuation May Hit Eisai's Epilepsy Succession
Fatality of healthy volunteer in early clinical trial prompts halt of all clinical work for candidate anti-epileptic, potentially hitting Eisai's product succession strategy in a core therapeutic area.
You may also be interested in...
New potentially effective therapy for drug-resistant epilepsy, seen as the most pressing unmet need in this market, is on the horizon as FDA begins approval review of SK’s cenobamate, also marking a first for the Korean pharma industry.
Japanese firm again links with an earlier venture capital partner and some familiar faces to progress its norovirus vaccine outside Japan.
Private California venture will bring additional expertise and novel platforms to acquisitive biotech giant as it looks to expand its interests in bispecific and multispecific antibody technologies.